After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

More than one-third of patients with systemic lupus erythematosus experience a flare after starting dialysis for end-stage ...

African Americans, particularly women, and residents of Southern states face disproportionately high rates of SLE-related mortality.

Charles River Laboratories International, Inc. CRL and Valo Health, Inc. recently announced an advanced product candidate for the treatment of different forms of lupus and other autoimmune indications ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

In a new study, researchers explored experiences, perceptions, and health effects of a newly developed healthy lifestyle ...

A minimum of 3 years of sustained clinical remission may protect against an increase in disease activity and the development ...

Assistant Professor Andrew Monteith's lab in the Department of Microbiology is documenting how key immune cells detect ...

Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T entering Phase 3 ...

New research suggests the use of oral prednisone should be limited in patients with systemic lupus erythematosus with a history of recurrent pericarditis.

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity and remission, and more time spent in those states, vs. standard therapy ...

Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of ...